Memory Aid by Intranasal Insulin in Diabetes (MemAID)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 289 participants.

Also called NCT02415556

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 289 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02415556
Other papers using this trial's data
  • MemAID: Memory advancement with intranasal insulin vs. placebo in type 2 diabetes and control participants: a randomized clinical trial Journal of neurology, 2022-09 DOI, PubMed 35482079, PMC9046533 In the PMC Open Access subset under a licence that is not Creative Commons.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02415556. Randomized; quadruple masking; primary purpose treatment. Start 2015-10-06 (actual); primary completion 2020-05-31 (actual). Results posted on 2021-09-17.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Memory Aid by Intranasal Insulin in Diabetes (MemAID)
Acronym
MemAID
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Regular Human Insulin
Intervention (Drug)
Placebo
Lead sponsor
Beth Israel Deaconess Medical Center (class: other)
Collaborator
Novo Nordisk A/S (class: industry)
Collaborator
Medtronic (class: industry)
Collaborator
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (class: US National Institutes of Health)

Record details

Record id
cardio:ct-nct02415556
Content hash
743bad261d80286ddde528cd04bfd90d8d91fca7e9986cbd1245a75115ea896a